Literature DB >> 24720328

Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners.

Robert H Quinn1, R Lor Randall, Joseph Benevenia, Sigurd H Berven, Kevin A Raskin.   

Abstract

Metastatic bone disease has a significant effect on a patient's mortality and health-related quality of life. An aging US population and improved survival rates of patients with cancer have led to an increase in the incidence of symptomatic bony metastatic lesions that may require orthopaedic care. Skeletal-related events in neoplastic disease include pain, pathologic fracture, hypercalcemia, and neural compression, including spinal cord compression. The clinical evaluation and diagnostic study of a patient with a skeletal lesion of unknown etiology should be approached carefully. In patients with widespread metastatic disease, the treatment of a skeletal-related event may be limited to stabilization of the pathologic fracture or local disease control. The treatment of metastatic bone disease is guided by the nature of the skeletal-related event, the responsiveness of the lesion to adjuvant care, and the overall condition and survival expectations of the patient. Impending pathologic fractures are often more easily treated, with less morbidity and easier recovery for patients, than completed fractures. Quality of life is the most important outcome measure in these patients. When surgery is indicated, the approach, choice of fixation, and use of adjuvant should allow for immediate and unrestricted weight bearing. Because metastatic lesions to the skeleton have a limited capacity for spontaneous healing, surgical fixation should be durable for the life expectancy of the patient. In the epiphyseal region of long bones, replacement arthroplasty is generally preferred over internal fixation. Metaphyseal and diaphyseal regions can generally be addressed with intramedullary nailing or plate fixation with adjuvant. The specific treatment of acetabular lesions is dictated by the anatomy and the degree of bone loss. Spinal stability and neural compromise are important considerations in choosing a strategy for managing spine tumors. Effective surgical approaches to metastatic disease of the spine may include vertebral augmentation or open decompression and realignment of the spinal column with internal fixation. Radiation therapy is an important adjunctive modality in the treatment of metastatic bone disease. Medical management consists of symptom control, cytotoxic chemotherapy, and targeted therapy. Emerging technologies, including radiofrequency ablation, cementoplasty, and advances in intraoperative imaging and navigation, show promise in the treatment of metastatic bone disease.

Entities:  

Mesh:

Year:  2014        PMID: 24720328

Source DB:  PubMed          Journal:  Instr Course Lect        ISSN: 0065-6895


  7 in total

1.  Are Allogeneic Blood Transfusions Associated With Decreased Survival After Surgery for Long-bone Metastatic Fractures?

Authors:  Stein J Janssen; Yvonne Braun; John E Ready; Kevin A Raskin; Marco L Ferrone; Francis J Hornicek; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2015-01-31       Impact factor: 4.176

Review 2.  New therapeutic targets for cancer bone metastasis.

Authors:  Jing Y Krzeszinski; Yihong Wan
Journal:  Trends Pharmacol Sci       Date:  2015-05-09       Impact factor: 14.819

3.  The Influence of Hospital Characteristics on Patient Survival in Surgically Managed Metastatic Disease of Bone: An Analysis of the SEER-Medicare Linked Database.

Authors:  Emma L Herbach; Bradley D McDowell; Elizabeth A Chrischilles; Benjamin J Miller
Journal:  Am J Clin Oncol       Date:  2022-07-06       Impact factor: 2.787

4.  Development and validation of a prognostic nomogram for the overall survival of patients living with spinal metastases.

Authors:  Xiong-Gang Yang; Jiang-Tao Feng; Feng Wang; Xin He; Hao Zhang; Li Yang; Hao-Ran Zhang; Yong-Cheng Hu
Journal:  J Neurooncol       Date:  2019-09-09       Impact factor: 4.130

5.  How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease-decision analysis and comparison of three international patient populations.

Authors:  Andrea Piccioli; M Silvia Spinelli; Jonathan A Forsberg; Rikard Wedin; John H Healey; Vincenzo Ippolito; Primo Andrea Daolio; Pietro Ruggieri; Giulio Maccauro; Alessandro Gasbarrini; Roberto Biagini; Raimondo Piana; Flavio Fazioli; Alessandro Luzzati; Alberto Di Martino; Francesco Nicolosi; Francesco Camnasio; Michele Attilio Rosa; Domenico Andrea Campanacci; Vincenzo Denaro; Rodolfo Capanna
Journal:  BMC Cancer       Date:  2015-05-22       Impact factor: 4.430

6.  Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: Meta-analysis.

Authors:  Yudong Zhang; Minhan Yi; Jie Cao; Can Hou; Yanyan Zhou; Yanjun Zhong
Journal:  J Int Med Res       Date:  2016-02-08       Impact factor: 1.671

Review 7.  A systematic review on in vitro 3D bone metastases models: A new horizon to recapitulate the native clinical scenario?

Authors:  Francesca Salamanna; Deyanira Contartese; Melania Maglio; Milena Fini
Journal:  Oncotarget       Date:  2016-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.